8-K Announcements
2Material company update
Aug 20, 2025·SEC
Material company update
Aug 15, 2024·SEC
GRI Bio, Inc.(GRI)Earnings, Financials & Key Ratios
GRI•NASDAQ
$1.87
Price updated Jun 27, 2026
AboutGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Show more
- Revenue$0-100.0%
- EBITDA-$12M-45.5%
- Net Income-$12M-45.7%
- EPS (Diluted)-121.80+92.1%
- ROE-238.17%+37.7%
GRI Price & Volume
GRI Bio, Inc. (GRI) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Capital Sustainability Outlook
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Shortfall
"GRI Bio remains a high-risk, pre-revenue biotechnology entity whose valuation is entirely dependent on the successful advancement of its NKT cell modulation platform. While the company maintains a clean balance sheet with a 0.01 debt-to-equity ratio, the lack of commercial revenue and consistent operating losses, which reached $3.4 million in 2025Q3, necessitate ongoing reliance on dilutive capital raises. Investors should monitor the company's ability to extend its cash runway beyond the current $11.0 million liquidity position as it navigates expensive Phase II clinical trials."
Verdict Logic
the company's persistent cash burn, highlighted by a $3.7 million free cash flow outflow in 2026Q1, presents a substantial risk of further shareholder dilution before any potential commercialization.
GRI Growth Metrics
GRI Bio, Inc. (GRI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-6.65%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM93.49%
Return on Capital
10 Years-1356.36%
5 Years-1670.22%
3 Years-1670.22%
Last Year-236.56%
Peers Comparison
Key metrics vs top competitors for GRI Bio, Inc. (GRI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.87 | $167.99K | -0.02 | -100% | — | -238.17% | — | |
| $1.42 | $37.75M | -0.76 | 257.14% | — | -170.86% | — | |
| $13.49 | $1.13B | -25.45 | — | — | -38.92% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $27.00 | $3.38B | -207.69 | 91.34% | -0.57% | -1.41% | — | |
| $58.01 | $295.54M | -2.28 | — | — | -61.81% | — |
Compare GRI vs Peers
GRI Bio, Inc. (GRI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GRI SEC Filings & Documents
GRI Bio, Inc. (GRI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when GRI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GRI Frequently Asked Questions
GRI Bio, Inc. (GRI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is GRI Bio, Inc. growing?
GRI Bio, Inc. (GRI) saw revenue decline by 100.0% over the past year.
Is GRI profitable?
GRI Bio, Inc. (GRI) reported a net loss of $10.7M for fiscal year 2025.
Dividend & Returns
What is GRI's return on equity?
GRI Bio, Inc. (GRI) has a return on equity (ROE) of -238.2%. Negative ROE indicates the company is unprofitable.
What is GRI Bio, Inc.'s free cash flow?
GRI Bio, Inc. (GRI) had negative free cash flow of $11.9M in fiscal year 2025, likely due to heavy capital investments.